Capitalization 6.57B 9.92B P/E ratio 2024 *
111x
P/E ratio 2025 * 55.3x
Enterprise value 3.15B 4.75B EV / Sales 2024 *
8.49x
EV / Sales 2025 * 6.62x
Free-Float
76.65%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.46%
1 week+1.91%
Current month+8.90%
1 month+11.11%
3 months+42.03%
6 months+82.15%
Current year+101.49%
More quotes
1 week
18.81
Extreme 18.81
20.76
1 month
17.42
Extreme 17.42
20.76
Current year
9.13
Extreme 9.13
20.76
1 year
8.20
Extreme 8.2
20.76
3 years
3.55
Extreme 3.55
20.76
5 years
0.76
Extreme 0.755
20.76
10 years
0.46
Extreme 0.46
20.76
More quotes
Insiders TitleAgeSince
Founder 49 15-10-31
Director of Finance/CFO 58 22-01-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Founder 49 15-10-31
Founder - 15-10-31
Chairman 83 17-09-16
More insiders

Other Biotechnology & Medical Research

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+3.46%+1.91%+81.99%+285.39% 4.36B
+1.12%+0.84%-3.11%-62.13% 46.95B
+0.12%+0.31%+6.24%-26.90% 41.67B
+9.20%+8.56%+7.43%+0.13% 44.71B
-0.94%-8.04%+17.75%+29.58% 29.8B
+2.82%+2.38%+27.95%-23.95% 28.65B
+3.10%-0.27%+38.22%+62.26% 28.11B
+1.05%+1.64%+34.00%+79.04% 14.76B
+3.77%-1.64%+78.24%+142.73% 13.51B
+3.06%+0.73%-13.03%-33.70% 12.26B
Average +2.41%+0.21%+27.57%+45.24% 26.48B
Weighted average by Cap. +2.27%+0.84%+17.40%+6.95%
See all sector performances
Ratios2024 *2025 *
Net sales 758M 1.14B 961M 1.45B
Net income 58.54M 88.37M 117M 177M
Net Debt -134M -202M -212M -321M
More financial data * Estimated data
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).
Employees
423
Calendar
Related indices
More about the company
Date Price Change Volume
24-07-23 20.31 $ +3.46% 1 964 627
24-07-22 19.63 $ +2.61% 1,028,681
24-07-19 19.13 $ -1.75% 6,335,507
24-07-18 19.47 $ -2.65% 2,365,093
24-07-17 20.00 $ +0.35% 1,441,090

Delayed Quote Australian S.E., July 23, 2024 at 02:10 am EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
19.63AUD
Average target price
20.87AUD
Spread / Average Target
+6.32%
Consensus

Profit revisions

Quarterly revenue - Rate of surprise